Crossmark

EFICÁCIA SUPERIOR DE DOLUTEGRAVIR (DTG) MAIS 2 INIBIDORES DA TRANSCRIPTASE REVERSA (ITRNS) COMPARADA COM LOPINAVIR/R MAIS 2 ITRNS NA SEGUNDA LINHA DE TRATAMENTO – DADOS DE 48 SEMANAS DO ESTUDO DAWNING

Crossref DOI link: https://doi.org/10.1016/j.bjid.2018.10.105

Published Print: 2018-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Aboud, Michael

Kaplan, Richard

Lombaard, Johannes

Zhang, Fujie

Hidalgo, José

Mamedova, Elmira

Losso, Marcelo

Chetchotisakd, Ploenchan

Brites, Carlos

Sievers, Jörg

Brown, Dannae

Hopking, Judy

Underwood, Mark

Nascimento, Maria Claudia

Gartland, Martin

Smith, Kimberly

Sarti, Rita Manzano
License Information

Text and Data Mining valid from 2018-12-01

Version of Record valid from 2018-11-10
More Information

This article is maintained by: Elsevier

Article Title: EFICÁCIA SUPERIOR DE DOLUTEGRAVIR (DTG) MAIS 2 INIBIDORES DA TRANSCRIPTASE REVERSA (ITRNS) COMPARADA COM LOPINAVIR/R MAIS 2 ITRNS NA SEGUNDA LINHA DE TRATAMENTO – DADOS DE 48 SEMANAS DO ESTUDO DAWNING

Journal Title: The Brazilian Journal of Infectious Diseases

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.bjid.2018.10.105

Content Type: simple-article

Copyright: Copyright © 2018 Published by Elsevier Editora Ltda.

Document is current

Any future updates will be listed below